CN114767832B - 多肽及其用途 - Google Patents

多肽及其用途 Download PDF

Info

Publication number
CN114767832B
CN114767832B CN202210427358.7A CN202210427358A CN114767832B CN 114767832 B CN114767832 B CN 114767832B CN 202210427358 A CN202210427358 A CN 202210427358A CN 114767832 B CN114767832 B CN 114767832B
Authority
CN
China
Prior art keywords
mice
polypeptide
leu
polypeptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210427358.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114767832A (zh
Inventor
谭震
李涛
李书鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Chenyang Biotechnology Co ltd
Original Assignee
Shenzhen Chenyang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chenyang Biotechnology Co ltd filed Critical Shenzhen Chenyang Biotechnology Co ltd
Priority to CN202210427358.7A priority Critical patent/CN114767832B/zh
Publication of CN114767832A publication Critical patent/CN114767832A/zh
Priority to JP2024561820A priority patent/JP2025516139A/ja
Priority to EP23791315.7A priority patent/EP4512412A4/en
Priority to PCT/CN2023/089490 priority patent/WO2023202663A1/zh
Priority to KR1020247037361A priority patent/KR20250013150A/ko
Application granted granted Critical
Publication of CN114767832B publication Critical patent/CN114767832B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/35—Animals modified by environmental factors, e.g. temperature, O2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202210427358.7A 2022-04-21 2022-04-21 多肽及其用途 Active CN114767832B (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202210427358.7A CN114767832B (zh) 2022-04-21 2022-04-21 多肽及其用途
JP2024561820A JP2025516139A (ja) 2022-04-21 2023-04-20 ポリペプチド及びその使用
EP23791315.7A EP4512412A4 (en) 2022-04-21 2023-04-20 POLYPEPTIDE AND ITS USES
PCT/CN2023/089490 WO2023202663A1 (zh) 2022-04-21 2023-04-20 多肽及其用途
KR1020247037361A KR20250013150A (ko) 2022-04-21 2023-07-25 폴리펩타이드 및 이의 용도

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210427358.7A CN114767832B (zh) 2022-04-21 2022-04-21 多肽及其用途

Publications (2)

Publication Number Publication Date
CN114767832A CN114767832A (zh) 2022-07-22
CN114767832B true CN114767832B (zh) 2025-05-16

Family

ID=82431759

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210427358.7A Active CN114767832B (zh) 2022-04-21 2022-04-21 多肽及其用途

Country Status (5)

Country Link
EP (1) EP4512412A4 (https=)
JP (1) JP2025516139A (https=)
KR (1) KR20250013150A (https=)
CN (1) CN114767832B (https=)
WO (1) WO2023202663A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114767832B (zh) * 2022-04-21 2025-05-16 深圳辰扬生物科技有限公司 多肽及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109106942A (zh) * 2018-09-18 2019-01-01 北京大学深圳研究生院 一种可通过血脑屏障的多肽在制备药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20080213271A1 (en) * 2005-05-05 2008-09-04 Center For Addiction And Mental Health Compositions and Methods For Modulating Dopamine Nerutransmission
CN107533049B (zh) * 2014-09-19 2020-11-20 皇家学习促进会/麦吉尔大学 用于监测细胞中生物分子的定位和运输的生物传感器
CN113501881B (zh) * 2017-09-27 2023-07-28 北京大学 融合蛋白
JP7492733B2 (ja) * 2020-07-21 2024-05-30 公立大学法人横浜市立大学 ドーパミンｄ２受容体・ドーパ受容体相互作用阻害ペプチド
CN113855784B (zh) * 2021-09-26 2025-04-15 深圳辰扬生物科技有限公司 多肽的抗抑郁、抗焦虑用途及复合体
CN113813364B (zh) * 2021-11-09 2024-06-28 深圳辰扬生物科技有限公司 多肽的抗成瘾及其复发的用途、复合体及多肽
CN114767832B (zh) * 2022-04-21 2025-05-16 深圳辰扬生物科技有限公司 多肽及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109106942A (zh) * 2018-09-18 2019-01-01 北京大学深圳研究生院 一种可通过血脑屏障的多肽在制备药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Modulation of D2R-NR2B Interactions in Response to Cocaine;Xian-Yu Liu等;《Neuron》;20061207;第52卷(第5期);第897-909页 *
Xian-Yu Liu等.Modulation of D2R-NR2B Interactions in Response to Cocaine.《Neuron》.2006,第52卷(第5期),第897-909页. *

Also Published As

Publication number Publication date
EP4512412A4 (en) 2026-04-22
EP4512412A1 (en) 2025-02-26
JP2025516139A (ja) 2025-05-27
WO2023202663A1 (zh) 2023-10-26
CN114767832A (zh) 2022-07-22
KR20250013150A (ko) 2025-01-31

Similar Documents

Publication Publication Date Title
KR102793383B1 (ko) 시누클레인병증의 치료를 위한 제제, 용도 및 방법
ES2637341T3 (es) Proteína de unión a neurotrofina P75NTR para su utilización terapéutica
US20200392217A1 (en) Human-derived anti-huntingtin (htt) antibodies and uses thereof
JP6725940B2 (ja) 抗血管新生活性を有するシンデカン−２のフラグメント
EA037416B1 (ru) Слитый белок для обезболивания и/или профилактики возникновения боли
AU2020313326A1 (en) Peptide therapeutics for autoimmune diseases and inflammatory diseases
JP2020500897A (ja) 補体活性のモジュレータ
CN113813364B (zh) 多肽的抗成瘾及其复发的用途、复合体及多肽
CN114767832B (zh) 多肽及其用途
CN113855784B (zh) 多肽的抗抑郁、抗焦虑用途及复合体
JP2016510596A (ja) ＰＴＤ−Ｓｍａｄ７薬物療法
Hao et al. Vaccination with platelet-derived growth factor B kinoids inhibits CCl4-induced hepatic fibrosis in mice
JP2006526382A (ja) 中枢神経系の損傷
WO2022103977A1 (en) Compositions and methods for controlled protein degradation in neurodegenerative disease
HK40121458A (en) Polypeptide and use thereof
US20220204564A1 (en) Compositions and methods of inhibiting the binding of plasma igg autoantibodies to serotonin 2a receptor
WO2023220118A2 (en) Compositions and methods for controlled protein degradation in neurodegenerative disease
CN119638819B (zh) 一种靶向降解tmem59多肽及其应用
Kim et al. Properties of GST-CALM expressed in E. coli
Altamore Use of peptide mimetics of proteins for characterization of immune response in different pathological conditions
KR101917419B1 (ko) Ｃｒｉｆ１을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물
US10125183B2 (en) Decoy peptides inhibiting binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1
CN118846108A (zh) 多肽dp9与载体蛋白的偶联物在制备药物中的应用
JP2005145936A (ja) 抗Ｋａｎｋモノクローナル抗体
CN1919868B (zh) 慢性神经痛相关蛋白及其基因

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant